Company intelligence / Profile preview

Hong Kong WD Pharmaceutical Co., Limited

Hong Kong, Hong Kong SAR, Chinaen.wdpharma.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has completed a Phase 2 clinical trial for WD-1603 (carbidopa/levodopa controlled-release tablets) in Parkinson's disease patients. Another Phase 2 trial (CTRI/2023/12/060430) for WD-1905 tablets compared with SINEMET® in Parkinson's Disease subjects with Morning Akinesia was initiated in December 2023 but is not yet recruiting[1][3].

Therapeutic areas: Neurology
Modalities: Small moleculescontrolled-release formulations
Industry: Biotech

Drug pipeline

1 asset

WD-1602

Beyond the preview

Go deeper on Hong Kong WD Pharmaceutical Co., Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hong Kong WD Pharmaceutical Co., Limited.

Explore the full profile